Rivaroxaban in the treatment of upper extremity deep vein thrombosis: A single-center experience and review of the literature

Schastlivtsev, Ilya; Lobastov, Kirill; Tsaplin, Sergey; Kanzafarova, Irina; Barinov, Victor; Laberko, Leonid; Родоман, Г. В.; Zhuravlev, Sergey

doi:10.1016/j.thromres.2019.07.008

Cited by 33 publications

(21 citation statements)

References 24 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…292 Similar good results were obtained in another study on 30 patients treated with rivaroxaban. 293 A more recent case control study comparing apixaban (n ¼ 63) or rivaroxaban (n ¼ 39) with LMWH and/or warfarin (n ¼ 108) concluded that DOACs appeared to be as safe and effective as LMWH and/or warfarin. 294 For patients with cancer associated UEDVT, long term LMWH monotherapy is preferred over the administration of VKAs.…”

Section: Treatmentmentioning

confidence: 99%

Editor's Choice – European Society for Vascular Surgery (ESVS) 2021 Clinical Practice Guidelines on the Management of Venous Thrombosis

Kakkos

Gohel²,

Bækgaard

et al. 2021

European Journal of Vascular and Endovascular Surgery

407

323

View full text Add to dashboard Cite

Section: Treatmentmentioning

confidence: 99%

Editor's Choice – European Society for Vascular Surgery (ESVS) 2021 Clinical Practice Guidelines on the Management of Venous Thrombosis

Kakkos

Gohel²,

Bækgaard

et al. 2021

European Journal of Vascular and Endovascular Surgery

407

323

View full text Add to dashboard Cite

“…There are no RCTs evaluating the DOACs for the treatment of UEDVT; however, several prospective 67‐70 or retrospective 71‐73 cohort studies were published in the past few years. Houghton et al 70 prospectively assessed a cohort of 210 patients with acute UEDVT evaluated at the Mayo Clinic in the years 2013‐2019: 102 treated with DOACs (63 apixaban, 39 rivaroxaban) and 108 treated with LMWH/VKAs.…”

Section: Upper Extremity Deep Vein Thrombosismentioning

confidence: 99%

“…There are no RCTs evaluating the DOACs for the treatment of UEDVT; however, several prospective [67][68][69][70] or retrospective [71][72][73] (2.0% vs 4.6%). 70 However, the presence of active cancer was more common in the standard treatment group.…”

Section: Evidence Regarding Doacsmentioning

confidence: 99%

Direct oral anticoagulants for unusual‐site venous thromboembolism

Riva

Ageno

2021

Research and Practice in Thrombosis and Haemostasis

View full text Add to dashboard Cite

Direct oral anticoagulants (DOACs) are currently the preferred oral anticoagulant treatment for most of the patients with deep vein thrombosis of the lower extremities and/or pulmonary embolism. DOACs have several advantages over vitamin K antagonists, such as availability of fixed dosages, fewer drug interactions, faster onset of action, shorter half‐life, and lower risk of major and intracranial bleeding. Although the evidence on the use of DOACs in patients with unusual‐site venous thromboembolism (VTE) is limited to a few, small randomized controlled trials, these drugs are increasingly used in clinical practice, and several observational cohort studies have been published recently. This narrative review will describe the latest evidence for the use of the DOACs in patients with thrombosis in atypical locations (splanchnic, cerebral, upper extremity, ovarian, and renal vein thrombosis) and will provide some practical advice for their use in patients with unusual‐site VTE.

show abstract

“…For example, there was an increased risk of thromboembolic and bleeding complications in patients with a mechanical heart valve treated with dabigatran in the RE-ALIGN study [ 45 ]. Data on direct oral anticoagulants (DOACs) for the treatment of UEDVT are very scarce, and include only small studies that mainly evaluated rivaroxaban ( Table 2 ) [ 17 , 46 , 47 , 48 , 49 , 50 ]. Nonetheless, since DOACs are recommended for patients with DVT of the lower extremities, these agents are increasingly being prescribed in patients with UEDVT [ 51 , 52 , 53 ].…”

Section: Treatmentmentioning

confidence: 99%

Diagnostic and Therapeutic Management of Upper Extremity Deep Vein Thrombosis

Bosch

Nisio

Büller

et al. 2020

JCM

View full text Add to dashboard Cite

Upper extremity deep vein thrombosis (UEDVT) accounts for 5% of all deep vein thromboses (DVTs). UEDVT may be complicated by post thrombotic syndrome and pulmonary embolism, and early recognition and prompt start of anticoagulant treatment are key. Primary UEDVT, also known as Paget-von Schrötter syndrome, is associated with repeated or sudden physical activity of the upper arm and venous outflow obstruction due to anatomical variations. Secondary UEDVT is often associated with malignancy or use of intravenous devices, such as central venous catheters or pacemaker leads. Although the diagnosis and treatment of UEDVT have many similarities with DVT of the lower extremities, knowledge of specific aspects regarding UEDVT is important to guide optimal management. In this review, we will discuss the epidemiology, diagnosis, and treatment of UEDVT based on the current literature.

show abstract

Rivaroxaban in the treatment of upper extremity deep vein thrombosis: A single-center experience and review of the literature

Cited by 33 publications

References 24 publications

Editor's Choice – European Society for Vascular Surgery (ESVS) 2021 Clinical Practice Guidelines on the Management of Venous Thrombosis

Editor's Choice – European Society for Vascular Surgery (ESVS) 2021 Clinical Practice Guidelines on the Management of Venous Thrombosis

Direct oral anticoagulants for unusual‐site venous thromboembolism

Diagnostic and Therapeutic Management of Upper Extremity Deep Vein Thrombosis

Contact Info

Product

Resources

About